H e m a t o lo g y E d u c a t io n - European Hematology Association

transplantation, 7,91 and generally within the first year.
Early detection of donor cells by increasing mixed
chimerism may be successfully eradicated by reducing
ongoing immunosuppressive therapy. 94 Donor lymphocyte
infusion (DLI) in JMML relapse is largely unsuccessful.
95 A second or even a third transplantation gives
a relatively high chance of survival. 8
References
1. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric
approach to the WHO classification of myelodysplastic and
myeloproliferative diseases. Leukemia. 2003;17:277-282.
2. Baumann I, Niemeyer CM, Bennett JM, Shannon K.
Childhood myelodysplastic syndrome. In: Swerdlow SH,
Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors.
WHO classification of tumours of haematopoietic and lymphoid
tissues. Lyon: IARC; 2008. p. 104-107.
3. Hasle H, Aricò M, Basso G, et al. Myelodysplastic syndrome,
juvenile myelomonocytic leukemia, and acute myeloid
leukemia associated with complete or partial monosomy 7.
Leukemia. 1999;13:376-385.
4. Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia
in childhood: a retrospective analysis of 67 patients with particular
reference to monosomy 7. Blood. 2003;102:1997-2003.
5. Hasle H, Baumann I, Bergsträsser E, et al. The International
Prognostic Scoring System (IPSS) for childhood myelodysplastic
syndrome (MDS) and juvenile myelomonocytic
leukemia (JMML). Leukemia. 2004;18:2008-2014.
6. Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational
spectrum of PTPN11 in juvenile myelomonocytic leukemia
and Noonan Syndrome/myeloproliferative disease. Blood.
2005;106:2183-2185.
7. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell
transplantation (HSCT) in children with juvenile
myelomonocytic leukemia (JMML): results of the EWOG-
MDS/EBMT trial. Blood. 2005;105(1):410-419.
8. Yoshimi A, Mohamed M, Bierings M, et al. Second allogeneic
hematopoietic stem cell transplantation (HSCT) results in
outcome similar to that of first HSCT for patients with juvenile
myelomonocytic leukemia. Leukemia. 2007; 21(3):556-
560.
9. Jaffe ES, Harris NL, Stein H, Vardiman JW. (Eds). World
Health Organization classification of tumours. Pathology and
genetics of tumours of haematopoietic and lymphoid tissues.
Lyon: IARC Press; 2001.
10. Swerdlow SH, Campo E, Harris NL, et al. WHO classification
of tumours of haematopoietic and lymphoid tissues. Lyon:
IARC; 2008.
11. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic
syndrome in Denmark: incidence and predisposing conditions.
Leukemia. 1995;9:1569-1572.
12. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz
KR. A population-based study of childhood myelodysplastic
syndrome in British Columbia, Canada. Br J Haematol. 1999;
106:1027-1032.
13. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill
PA, Stiller CA. Paediatric MDS and JMML in the UK: a population
based study of incidence and survival. Br J Haematol.
2003;121:758-767.
14. Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome
in childhood: a retrospective study of 189 patients in
Japan. Leukemia. 2001;15:1713-1720.
15. Niemeyer CM, Aricò M, Basso G, et al. Chronic myelomonocytic
leukemia in childhood: a retrospective analysis of 110
cases. Blood. 1997;89:3534-3543.
16. Stary J, Baumann I, Creutzig U, Harbott J, Michalova K,
Niemeyer C. Getting the numbers straight in pediatric MDS:
distribution of subtypes after exclusion of down syndrome.
Pediatr Blood Cancer. 2008; 50(2):435-436.
17. Rosenberg PS, Huang Y, Alter BP. Individualized risks of first
adverse events in patients with Fanconi anemia. Blood. 2004;
104:350-355.
18. Alter BP, Giri N, Savage SA, et al. Malignancies and survival
patterns in the National Cancer Institute inherited bone marrow
failure syndromes cohort study. Br J Haematol. 2010;150
(2):179-188.
19. Calado RT, Young NS. Telomere diseases. N Engl J Med.
2009;361(24):2353-2365.
20. Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term
London, United Kingdom, June 9-12, 2011
risk of leukaemia in patients with severe congenital neutropenia
maintained on G-CSF therapy. Br J Haematol. 2010;150
(2):196-199.
21. Delhommeau F, Dupont S, Della V, et al. Mutation in TET2 in
myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
22. Muramatsu H, Makishima H, Jankowska AM, et al.
Mutations of E3 ubiquitin ligase Cbl family members but not
TET2 mutations are pathogenic in juvenile myelomonocytic
leukemia. Blood. 2010;115:1069-1975.
23. Maserati E, Minelli A, Pressato B, et al. Shwachman syndrome
as mutator phenotype responsible for myeloid dysplasia/neoplasia
through karyotype instability and chromosomes
7 and 20 anomalies. Genes Chromosomes Cancer.
2006;45(4):375-382.
24. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor
gene WT1 is a good marker for diagnosis of disease progression
of myelodysplastic syndromes. Leukemia. 1999;13(3):
393-399.
25. Cantù-Rajnoldi A, Fenu S, Kerndrup G, van Wering ER,
Niemeyer CM, Baumann I. Evaluation of dysplastic features
in myelodysplastic syndromes: experience from the morphology
group of the European Working Group of MDS in
Childhood (EWOG-MDS). Ann Hematol. 2005; 84(7):429-
433.
26. Barnard DR, Kalousek DK, Wiersma SR, et al. Morphologic,
immunologic, and cytogenetic classification of acute myeloid
leukemia and myelodysplastic syndrome in childhood: a
report from the Childrens Cancer Group. Leukemia. 1996;10:
5-12.
27. Göhring G, Michalova K, Beverloo HB, et al. Complex karyotype
newly defined: the strongest prognostic factor in
advanced childhood myelodysplastic syndrome. Blood. 2010;
116(19):3766-3799.
28. Hasle H, Clausen N, Pedersen B, Bendix-Hansen K.
Myelodysplastic syndrome in a child with constitutional trisomy
8 mosaicism and normal phenotype. Cancer Genet
Cytogenet. 1995;79:79-81.
29. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic
bone marrow transplantation, autologous bone marrow
transplantation, and aggressive chemotherapy in children
with acute myeloid leukemia in remission. Blood.
2001;97(1):56-62.
30. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelo -
dysplastic and myeloproliferative disorders of childhood: a
study of 167 patients. Blood. 1999;93:459-466.
31. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study
of 90 children requiring treatment for juvenile myelomonocytic
leukemia or myelodysplastic syndrome: A report from
the Children’s Cancer Group. J Clin Oncol. 2002;20:434-440.
32. Veltroni M, Sainati L, Zecca M, et al. Advanced pediatric
myelodysplastic syndromes: can immunophenotypic characterization
of blast cells be a diagnostic and prognostic tool?
Pediatr Blood Cancer. 2009;52(3):357-363.
33. Al-Rahawan MM, Alter BP, Bryant BJ, Elghetany MT. Bone
marrow cell cycle markers in inherited bone marrow failure
syndromes. Leuk Res. 2008;32:1793-1799.
34. Hasle H, Kerndrup G, Yssing M, et al. Intensive chemotherapy
in childhood myelodysplastic syndrome. A comparison
with results in acute myeloid leukemia. Leukemia.
1996;10:1269-1273.
35. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome
is not merely “preleukemia”. Blood. 2002;100(3):791-
798.
36. Vardiman JW, Harris NL, Brunning RD. The World Health
Organization (WHO) classification of the myeloid neoplasms.
Blood. 2002;100(7):2292-2302.
37. Yoshimi A, Baumann I, Fuhrer M, et al. Immunosuppressive
therapy with anti-thymocyte globulin and cyclosporine A in
selected children with hypoplastic refractory cytopenia.
Haematologica. 2007;92(3):397-400.
38. Hasegawa D, Manabe A, Yagasaki H, et al. Treatment of children
with refractory anemia: the Japanese Childhood MDS
Study Group trial (MDS99). Pediatr Blood Cancer.
2009;53(6):1011-1015.
39. Webb DKH, Passmore SJ, Hann IM, Harrison G, Wheatley K,
Chessells JM. Results of treatment of children with refractory
anaemia with excess blasts (RAEB) and RAEB in transformation
(RAEBt) in Great Britain 1990-99. Br J Haematol. 2002;
117:33-39.
40. Creutzig U, Bender-Götze C, Ritter J, et al. The role of intensive
AML-specific therapy in treatment of children with
RAEB and RAEB-T. Leukemia. 1998;12:652-659.
41. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and
deletion 7q in children and adolescents with acute myeloid
Hematology Education: the education programme for the annual congress of the European Hematology Association | 2011; 5(1) | 299 |